Alice Fabarius
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alice Fabarius has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Hochhaus
Klinik für Innere Medizin II, Universitätsklinikum Jena, Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany
3 shared publications A. Kramer
Clinical Cooperation Unit Molekulare Hämatologie/Onkologie, DKFZ and Department of Internal Medicine V, Universität Heidelberg, Heidelberg
1 shared publicationB. Rebacz
Clinical Cooperation Unit Molekulare Hämatologie/Onkologie, DKFZ and Department of Internal Medicine V, Universität Heidelberg, Heidelberg
1 shared publication- Birgit Spiess
Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany
1 shared publication C. Haferlach
MLL Münchner Leukämielabor GmbH, München, Germany
1 shared publicationChristel Weiss
Abteilung für Medizinische Statistik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
1 shared publication
Latest Publications
- 1 August 2008
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 93 (8) , 1145-1154
Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib
Background Dasatinib is a multitargeted inhibitor of ABL, the SRC family, and other tyrosine kinases. We sought to evaluate the effects of this drug on cell proliferation, centrosomes, mitotic spindles, and cell cycle progression in vitro and in vivo . Design and Methods Human dermal fibroblasts, Chinese hamster cells, human osteosarcoma cells, and blood and bone marrow mononuclear cells from 32 patients with chronic myeloid leukemia, gastrointestinal stromal tumor, and systemic mastocytosis as well as from six healthy individuals were investigated. The effects of dasatinib were compared with those of the ABL inhibitors imatinib and nilotinib, the SRC inhibitor PP2, and the ABL/LYN inhibitor INNO-406. Results Dasatinib induced G1 phase arrest in all cell lines and this was associated with a decline in cyclin D1 levels. In vitro , centrosomal aberrations, a decrease of mitotic spindles, and G1 phase arrest were observed. In patients, centrosome alterations were found in a median of 17% (range, 10–22%) of cells with a decrease of spindles in 8/18 patients. In comparison, imatinib, nilotinib and PP2 led to centrosome aberrations without G1 phase arrest. INNO-406 was associated with centrosome aberrations and cell cycle arrest in G1 phase. Conclusions Dasatinib blocks the G1/S transition and inhibits cell growth. It induces centrosomal aberrations and a decrease of mitotic spindles. The effects suggest an involvement of SRC and ABL inhibition.
- 1 August 2008
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 93 (8) , 1145-1154
Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib
Background Dasatinib is a multitargeted inhibitor of ABL, the SRC family, and other tyrosine kinases. We sought to evaluate the effects of this drug on cell proliferation, centrosomes, mitotic spindles, and cell cycle progression in vitro and in vivo . Design and Methods Human dermal fibroblasts, Chinese hamster cells, human osteosarcoma cells, and blood and bone marrow mononuclear cells from 32 patients with chronic myeloid leukemia, gastrointestinal stromal tumor, and systemic mastocytosis as well as from six healthy individuals were investigated. The effects of dasatinib were compared with those of the ABL inhibitors imatinib and nilotinib, the SRC inhibitor PP2, and the ABL/LYN inhibitor INNO-406. Results Dasatinib induced G1 phase arrest in all cell lines and this was associated with a decline in cyclin D1 levels. In vitro , centrosomal aberrations, a decrease of mitotic spindles, and G1 phase arrest were observed. In patients, centrosome alterations were found in a median of 17% (range, 10–22%) of cells with a decrease of spindles in 8/18 patients. In comparison, imatinib, nilotinib and PP2 led to centrosome aberrations without G1 phase arrest. INNO-406 was associated with centrosome aberrations and cell cycle arrest in G1 phase. Conclusions Dasatinib blocks the G1/S transition and inhibits cell growth. It induces centrosomal aberrations and a decrease of mitotic spindles. The effects suggest an involvement of SRC and ABL inhibition.
- Open Access
- 3 July 2007
- Published by Wiley in British Journal of Haematology
- Vol. 138 (3) , 369-373
Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability
- 3 July 2007
- Published by Wiley in British Journal of Haematology
- Vol. 138 (3) , 369-373
Open AccessCentrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability
- 30 June 2005
- Published by Springer Nature in Leukemia
- Vol. 19 (9) , 1573-1578
Induction of centrosome and chromosome aberrations by imatinib in vitro
Imatinib (STI571, Gleevec/Glivec) is a potent selective tyrosine kinase inhibitor and is used successfully in the treatment of chronic myeloid leukemia (CML). While karyotype alterations, in addition to the Philadelphia chromosome, are a common phenomenon of progressing CML, the observation of BCR-ABL-negative leukemic clones with distinct aberrant karyotypes under an imatinib regimen is not yet understood. Here we test the hypothesis that such tumor clones may be induced de novo from normal cells by imatinib. In vitro experiments with varying drug concentrations (5–20 M) were performed on normal human dermal fibroblasts (NHDF), Chinese hamster embryonal and Indian muntjak fibroblasts. After 3 weeks of treatment, analysis of cell cultures by centrosome immunostaining and conventional cytogenetics revealed that imatinib induced centrosome and chromosome aberrations in all cultures in a significant dose-dependent and species-independent manner. Moreover, the results of NHDF long-term culture experiments demonstrated that aberrant phenotypes, emerging under imatinib treatment for 12 weeks, were not reversible after prolonged propagation omitting the drug. These observations suggest a causative role of imatinib in the origin of centrosome and karyotype aberrations (genetic instability) and thus may explain the emergence of clonal chromosomal abnormalities in BCR-ABL-negative progenitor cells under imatinib therapy.
- 30 June 2005
- Published by Springer Nature in Leukemia
- Vol. 19 (9) , 1573-1578
Induction of centrosome and chromosome aberrations by imatinib in vitro
Imatinib (STI571, Gleevec/Glivec) is a potent selective tyrosine kinase inhibitor and is used successfully in the treatment of chronic myeloid leukemia (CML). While karyotype alterations, in addition to the Philadelphia chromosome, are a common phenomenon of progressing CML, the observation of BCR-ABL-negative leukemic clones with distinct aberrant karyotypes under an imatinib regimen is not yet understood. Here we test the hypothesis that such tumor clones may be induced de novo from normal cells by imatinib. In vitro experiments with varying drug concentrations (5–20 M) were performed on normal human dermal fibroblasts (NHDF), Chinese hamster embryonal and Indian muntjak fibroblasts. After 3 weeks of treatment, analysis of cell cultures by centrosome immunostaining and conventional cytogenetics revealed that imatinib induced centrosome and chromosome aberrations in all cultures in a significant dose-dependent and species-independent manner. Moreover, the results of NHDF long-term culture experiments demonstrated that aberrant phenotypes, emerging under imatinib treatment for 12 weeks, were not reversible after prolonged propagation omitting the drug. These observations suggest a causative role of imatinib in the origin of centrosome and karyotype aberrations (genetic instability) and thus may explain the emergence of clonal chromosomal abnormalities in BCR-ABL-negative progenitor cells under imatinib therapy.